## Molly McCloskey

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4903196/publications.pdf

Version: 2024-02-01

1478505 1720034 7 201 6 7 citations h-index g-index papers 8 8 8 284 docs citations times ranked citing authors all docs

#	ARTICLE	IF	CITATIONS
1	Repurposing Infectious Disease Hits as Anti- <i>Cryptosporidium</i> Leads. ACS Infectious Diseases, 2021, 7, 1275-1282.	3.8	8
2	Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learned. International Journal for Parasitology, 2020, 50, 413-422.	3.1	37
3	Development of 5-Aminopyrazole-4-carboxamide-based Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy. Journal of Medicinal Chemistry, 2019, 62, 3135-3146.	6.4	27
4	7H-Pyrrolo[2,3-d]pyrimidin-4-amine-Based Inhibitors of Calcium-Dependent Protein Kinase 1 Have Distinct Inhibitory and Oral Pharmacokinetic Characteristics Compared with 1H-Pyrazolo[3,4-d]pyrimidin-4-amine-Based Inhibitors. ACS Infectious Diseases, 2018, 4, 516-522.	3.8	5
5	Screening of the Pathogen Box for inhibitors with dual efficacy against Giardia lamblia and Cryptosporidium parvum. PLoS Neglected Tropical Diseases, 2018, 12, e0006673.	3.0	37
6	Development of a murine vertical transmission model for Toxoplasma gondii oocyst infection and studies on the efficacy of bumped kinase inhibitor (BKI)-1294 and the naphthoquinone buparvaquone against congenital toxoplasmosis. Journal of Antimicrobial Chemotherapy, 2017, 72, 2334-2341.	3.0	52
7	Advances in bumped kinase inhibitors for human and animal therapy for cryptosporidiosis. International Journal for Parasitology, 2017, 47, 753-763.	3.1	30